Crescent is developing applications for its technology in a number of growing markets and would welcome discussions with companies with an interest in the sectors.
The ultimate aim of our strategy is the address the underdiagnosis and undertreatment of women at risk of osteoporotic fracture.
Reference Labs
Crescent’s BQT® test will offer the predictive marker and associated instrumentation as a high value esoteric lab test for major reference laboratories worldwide. The technology is well suited to high throughput applications.
Physician Operated Labs
We offer a solution which is more value creating than DXA in a POL environment and brings osteoporosis testing to practices where DXA would not be cost effective.
Companion Diagnostics
The BQT® can support sales of anti-fracture pharmaceutical drugs by identifying women who will benefit at an earlier age, and with more accuracy that the current reference standard, DXA.
